Rebif sales rise 13% to €381 million; Erbitux sales up 33% to ‚€177million. Liquid Crystals climbing, revenues at‚ €211 million. R&D expenses up 17% to‚ €333 million. Group guidance for 2009 confirmed and refined.
Merck KGaA announced today that Group total revenues rose 2.7% in the third quarter to €1,944 million from €1,893
million in the year-ago quarter as the Pharmaceuticals divisions continued to grow and the Chemicals divisions continued to recover from the economic crisis.
Royalty income declined 9.7% to €82 million.
Mainly due to inventory adjustments and under utilisation of capacities, the gross margin was little changed compared to the year-ago quarter at €1,422 million.
For more information, please click the link below.